Wilson Sonsini Goodrich & Rosati's legacy closely traces the birth and evolution of Silicon Valley.
For nearly six decades, Wilson Sonsini has represented the technology pioneers associated with virtually every milestone innovation.
Today, the firm is synonymous with ushering promising, innovative companies through their business life cycle.
Careers
We look for the best and brightest of tomorrow and develop careers from the ground up.
News and Featured Insights
Bylined Articles
Leading Matters
Client Highlights
Wilson Sonsini Advises Simplify Medical in Its Acquisition by NuVasive
On February 24, 2021, NuVasive, Inc., the leader in spine technology innovation, focused on transforming spine surgery with minimally disruptive, procedurally integrated solutions, announced that it has acquired Simplify Medical, a privately held company and developer of the Simplify® Cervical Artificial Disc (Simplify Disc) for cervical total disc replacement (cTDR). Wilson Sonsini Goodrich & Rosati represented Simplify Medical in the transaction.
Client Highlights
Firm Advises Lilly Asia Ventures on Regor Therapeutics’ $90 Million Series B Financing
On February 18, 2021, Regor Therapeutics, a clinical-stage biotechnology company dedicated to the discovery of innovative medicines to treat cancer, immune disorders, and metabolic diseases, announced the completion of a $90 million Series B financing. The financing was led by Lilly Asia Ventures and included participation from Loyal Valley Capital, Lanting Capital, TF Capital, and Vertex Ventures China. Wilson Sonsini Goodrich & Rosati advised Lilly Asia Ventures on IP matters related to the transaction.
Regor Therapeutics was founded in 2018 by a group of veteran drug hunters with extensive research and leadership experience at top multinational pharmaceutical companies. It is committed to delivering clinically differentiated, best- and first-in-class drugs to serve patients globally. By leveraging computer accelerated rational discovery (CARD), a proprietary enabling technology platform, the team has successfully advanced numerous discovery programs in a dramatically accelerated fashion.
The Wilson Sonsini team that advised Lilly Asia Ventures on the financing included Senior Of Counsel Karen Wong, Of Counsel Richard Wang, patent agent Brandon Tavshanjian, and IP specialist Quinn Yu.
For more information, please see Regor Therapeutics’ press release.
Regor Therapeutics was founded in 2018 by a group of veteran drug hunters with extensive research and leadership experience at top multinational pharmaceutical companies. It is committed to delivering clinically differentiated, best- and first-in-class drugs to serve patients globally. By leveraging computer accelerated rational discovery (CARD), a proprietary enabling technology platform, the team has successfully advanced numerous discovery programs in a dramatically accelerated fashion.
The Wilson Sonsini team that advised Lilly Asia Ventures on the financing included Senior Of Counsel Karen Wong, Of Counsel Richard Wang, patent agent Brandon Tavshanjian, and IP specialist Quinn Yu.
For more information, please see Regor Therapeutics’ press release.
Client Highlights
Wilson Sonsini Advises Perrone Robotics on $10 Million Financing
On February 22, 2021, CapStone Holdings, a business incubator and investment group, announced a $10 million equity investment in Perrone Robotics, a leading provider of fully autonomous vehicle systems. Wilson Sonsini Goodrich & Rosati advised Perrone Robotics in the transaction.
Perrone delivers mobility excellence through the world’s first and only patented general purpose robotics operating system and autonomous vehicle retrofit kit, TONY. TONY embeds inside any vehicle, for any job, to provide a complete “artificial driver” solution that brings full autonomy in a safety certifiable framework for the right vehicle platform. Perrone’s solution helps commercial, municipal, and governmental customers increase transportation efficiencies, enhance safety, and accelerate zero-emission electric vehicle deployment.
Perrone will utilize a portion of the investment to establish an advanced autonomous vehicle testing facility at the American Center for Mobility (ACM) in Southeast Michigan. ACM is a collaborative effort of government, industry, and academic organizations focused on accelerating the mobility industry through testing, research, standards development, and educational programming. The new test facility will enable advanced, high-speed, and continuous testing of autonomous transit vans, shuttles, and other vehicles equipped with Perrone's TONY product.
The Wilson Sonsini team that advised Perrone Robotics on the financing includes Mark Fitzgerald, Tim Featherston, and Tamara Labanowski.
For more information, please see CapStone’s press release.
Perrone delivers mobility excellence through the world’s first and only patented general purpose robotics operating system and autonomous vehicle retrofit kit, TONY. TONY embeds inside any vehicle, for any job, to provide a complete “artificial driver” solution that brings full autonomy in a safety certifiable framework for the right vehicle platform. Perrone’s solution helps commercial, municipal, and governmental customers increase transportation efficiencies, enhance safety, and accelerate zero-emission electric vehicle deployment.
Perrone will utilize a portion of the investment to establish an advanced autonomous vehicle testing facility at the American Center for Mobility (ACM) in Southeast Michigan. ACM is a collaborative effort of government, industry, and academic organizations focused on accelerating the mobility industry through testing, research, standards development, and educational programming. The new test facility will enable advanced, high-speed, and continuous testing of autonomous transit vans, shuttles, and other vehicles equipped with Perrone's TONY product.
The Wilson Sonsini team that advised Perrone Robotics on the financing includes Mark Fitzgerald, Tim Featherston, and Tamara Labanowski.
For more information, please see CapStone’s press release.
Client Highlights
Wilson Sonsini Advises Lead Investors on Vividion’s $135 Million Series C
On February 24, 2021, Vividion Therapeutics, Inc., a biotechnology company focused on developing highly selective small molecule medicines that drug traditionally inaccessible targets, announced the completion of a $135 million Series C financing. The financing was co-led by new investors Logos Capital and Boxer Capital of Tavistock Group. Wilson Sonsini Goodrich & Rosati advised the lead investors on the financing.
Client Highlights
Wilson Sonsini Advises Highland Electric Transportation in $169 Million Electric Bus Deal, Largest of Its Kind in U.S.
On February 23, 2021, the Board of Education in Maryland's Montgomery County voted unanimously to approve a 16-year, $169 million contract to lease 326 buses, part of a plan that could result in the county replacing its entire 1,422-bus fleet over the next two decades. The vehicles will be built by Thomas Built Buses, a division of Daimler AG, with electric battery technology provided by Proterra, in a deal coordinated by Highland Electric Transportation. Highland will provide buses, install charging facilities at the county's bus depots, and train drivers. The company will also provide maintenance and manage the charging operation. Wilson Sonsini Goodrich & Rosati represented Highland Electric Transportation in the deal.
Client Highlights
Wilson Sonsini Advises General Atlantic on Patent Matters Related to Centessa Pharmaceuticals' Launch and $250 Million Series A
On February 16, 2021, Centessa Pharmaceuticals (Centessa) launched as a novel asset-centric pharmaceutical company designed and built to advance a portfolio of highly validated programs. Centessa’s asset-centric R&D model applied at scale has assembled best-in-class or first-in-class assets, each of which is led by specialized teams committed to accelerate development and reshape the traditional drug development process. The company was founded by Medicxi and raised $250 million in an oversubscribed Series A financing led by General Atlantic and co-led by Vida Ventures and Janus Henderson Investors. Additional blue-chip investors participated in the financing, including Boxer Capital, Cormorant Asset Management, T. Rowe Price Associates, Venrock Healthcare Capital Partners, Wellington Management Company, BVF Partners L.P., EcoR1 Capital, Franklin Templeton, Logos Capital, Samsara BioCapital, LifeSci Venture Partners, and an undisclosed U.S.-based, healthcare-focused fund. Wilson Sonsini Goodrich & Rosati advised General Atlantic on patent matters related to the transaction.
2020 Technology and Life Sciences IPO Report
Wilson Sonsini’s 2020 Technology and Life Sciences IPO Report presents analysis and data related to the pricing of 123 initial public offerings completed by U.S.-based technology and life sciences companies between January 1 and December 31, 2020. The report includes IPO filing, pricing, and value statistics for both sectors; governance and board of director details; ownership and structure factors; and defensive measure data points. It also considers concurrent private placements, indications of interest, direct listings, and special purpose acquisition companies.